Buprenorphine is shown to be an effective medication for the treatment of opioid use disorder. It promotes long-term recovery and decreases the risk of mortality. Although Medicaid programs largely cover buprenorphine products, many continue to apply prior authorization (PA) requirements.
This report studies how state Medicaid programs apply PA requirements to buprenorphine products.
Array
Report
Array
https://www.healthworkforceta.org/wp-content/uploads/2023/07/BHWRC_Coverage-of-Buprenorphine-Medications.pdf
February 2, 2021
Array, Array, Array, Array, Array
February 2, 2021